Skip to main content
Data show positive results for Boston Scientific's Lotus heart valve
5/17/2017

Data from a trial presented at the annual EuroPCR conference showed the use of Boston Scientific's Lotus heart valve in high-risk aortic stenosis patients led to a lower combined rate of mortality, valvular leakage and disabling stroke after one year, compared with Medtronic's CoreValve device. However, more Lotus device patients required a permanent pacemaker within 30 days of implantation.

Full Story: